News

NPS Pharmaceuticals, a biopharmaceutical company engaged in the development of specialty therapeutics to treat gastrointestinal and endocrine disorders, has reported a net loss of $8.48m, or $0.18 per

According to Therative, ThermaClear is safe on all skin types and tones and does not cause the drying, irritation or skin hyper pigmentation often associated with many topical

These results are substantially in line with management expectations. They reflect budgeted sales and marketing initiatives to promote the Previstage GCC Colorectal Cancer Staging Test and further product

Progenics Pharmaceuticals, a biopharmaceutical company, has reported a net loss of $14.6m, or $0.49 per share, for the fourth quarter of 2008, compared to a net loss of

Persistent activation of the Akt pathway has been found to play an important role in oncogenesis and chemo- and radiation-resistance and to be responsible for cancer cell proliferation,

MLR-1023 was discovered and developed internally using Melior’s indications discovery platform, theraTRACE. Andrew Reaume, president and CEO of Melior, said: “We are delighted to have been given the

Cytori offered the securities in this transaction pursuant to an effective shelf registration statement. The funds will be used for sales and marketing activities related to the commercialization

According to the company, this novel test incorporates 10 biomarkers, two of which are proprietary, along with a proprietary algorithm to help physicians diagnose patients with irritable bowel

In 2008, Voboril, 66, retired as chairman of Greatbatch, Inc., where he served as chief executive officer from 1990 to 2006. During his tenure at Greatbatch, he led